SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lodder MC, van Pelt PA, Lems WF, Kostense PJ, Koks CH, Dijkmans BA. Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2003; 30: 20801.
  • 2
    Valleala H, Laasonen L, Koivula MK, Mandelin J, Friman C, Risteli J, et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003; 30: 46873.
  • 3
    Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001; 29: 5539.
  • 4
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 147887.
  • 5
    Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, et al. NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002; 17: 120010.
  • 6
    Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9: 264358.
  • 7
    Rogers M, Frith J, Luckman S, Coxon F, Benford H, Monkkonen J, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24: 73S9S.
  • 8
    Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590607.
  • 9
    Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899911.
  • 10
    Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003; 17: 248195.
  • 11
    Sevilla L, Aperlo C, Dulic V, Chambard JC, Boutonnet C, Pasquier O, et al. The Ets2 transcription factor inhibits apoptosis induced by colony-stimulating factor 1 deprivation of macrophages through a Bcl-xL-dependent mechanism. Mol Cell Biol 1999; 19: 262434.
  • 12
    Woo KM, Kim HM, Ko JS. Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L). Exp Mol Med 2002; 34: 3406.
  • 13
    Boyce BF, Wright K, Reddy SV, Koop BA, Story B, Devlin R, et al. Targeting simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts. Endocrinology 1995; 136: 57519.
  • 14
    Hentunen TA, Reddy SV, Boyce BF, Devlin R, Park HR, Chung H, et al. Immortalization of osteoclast precursors by targeting Bcl -XL and Simian virus 40 large T antigen to the osteoclast lineage in transgenic mice. J Clin Invest 1998; 102: 8897.
  • 15
    Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFκB activation in primary hippocampal neurons. J Biol Chem 1999; 274: 85318.
  • 16
    Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A 1999; 96: 913641.
  • 17
    Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFκB, STAT and AP1 transcription factor families. Histol Histopathol 2001; 16: 595601.
  • 18
    Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 1997; 11: 348296.
  • 19
    Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. Bone and haematopoietic defects in mice lacking c-Fos. Nature 1992; 360: 7415.
  • 20
    Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity 1997; 6: 43747.
  • 21
    Yamamoto H, Flannery ML, Kupriyanov S, Pearce J, McKercher SR, Henkel GW, et al. Defective trophoblast function in mice with a targeted mutation of Ets2. Genes Dev 1998; 12: 131526.
  • 22
    Redlich K, Kiener HP, Schett G, Tohidast-Akrad M, Selzer E, Radda I, et al. Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor α. Arthritis Rheum 2001; 44: 26674.
  • 23
    Grall F, Gu X, Tan L, Cho JY, Inan MS, Pettit AR, et al. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor α in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor κB–mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003; 48: 124960.
  • 24
    Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR. The transcription factors hypoxia-inducible factor 1α and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum 2004; 50: 2916.
  • 25
    Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 402531.
  • 26
    Kitamura T, Onishi M, Kinoshita S, Shibuya A, Miyajima A, Nolan GP. Efficient screening of retroviral cDNA expression libraries. Proc Natl Acad Sci U S A 1995; 92: 914650.
  • 27
    Zaldumbide A, Carlotti F, Pognonec P, Boulukos KE. The role of the Ets2 transcription factor in the proliferation, maturation, and survival of mouse thymocytes. J Immunol 2002; 169: 487381.
  • 28
    Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 10636.
  • 29
    Xing L, Venegas AM, Chen A, Garrett-Beal L, Boyce BF, Varmus HE, et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001; 15: 24153.
  • 30
    Xing L, Carlson L, Story B, Tai Z, Keng P, Siebenlist U, et al. Expression of either NF-κB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J Bone Miner Res 2003; 18: 2609.
  • 31
    Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000; 278: 17584.
  • 32
    Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10: 116577.
  • 33
    Suda K, Woo JT, Takami M, Sexton PM, Nagai K. Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-α, IL-1, and RANKL. J Cell Physiol 2002; 190: 1018.
  • 34
    Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, et al. Tumor necrosis factor-α/nuclear transcription factor-κB signaling in periprosthetic osteolysis. J Orthop Res 2000; 18: 47280.
  • 35
    Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 14818.
  • 36
    Hirabayashi H, Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet 2003; 42: 131930.
  • 37
    Sevilla L, Zaldumbide A, Carlotti F, Dayem MA, Pognonec P, Boulukos KE. Bcl-XL expression correlates with primary macrophage differentiation, activation of functional competence, and survival and results from synergistic transcriptional activation by Ets2 and PU.1. J Biol Chem 2001; 276: 178007.
  • 38
    Akiyama T, Bouillet P, Miyazaki T, Kadono Y, Chikuda H, Chung UI, et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 2003; 22: 665364.
  • 39
    Abbas S, Abu-Amer Y. Dominant-negative IκB facilitates apoptosis of osteoclasts by tumor necrosis factor-α. J Biol Chem 2003; 278: 2007782.
  • 40
    Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, et al. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol 2000; 148: 33342.
  • 41
    Raouf A, Seth A. Ets transcription factors and targets in osteogenesis. Oncogene 2000; 19: 645563.
  • 42
    Sumarsono SH, Wilson TJ, Tymms MJ, Venter DJ, Corrick CM, Kola R, et al. Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature 1996; 379: 5347.
  • 43
    So H, Rho J, Jeong D, Park R, Fisher DE, Ostrowski MC, et al. Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem 2003; 278: 2420916.
  • 44
    Jin DI, Jameson SB, Reddy MA, Schenkman D, Ostrowski MC. Alterations in differentiation and behavior of monocytic phagocytes in transgenic mice that express dominant suppressors of ras signaling. Mol Cell Biol 1995; 15: 693703.
  • 45
    Smith JL, Schaffner AE, Hofmeister JK, Hartman M, Wei G, Forsthoefel D, et al. Ets-2 is a target for an akt (protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice. Mol Cell Biol 2000; 20: 802634.
  • 46
    Fowles LF, Martin ML, Nelsen L, Stacey KJ, Redd D, Clark YM, et al. Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling. Mol Cell Biol 1998; 18: 514856.
  • 47
    Lee SE, Chung WJ, Kwak HB, Chung CH, Kwack KB, Lee ZH, et al. Tumor necrosis factor-α supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001; 276: 493439.
  • 48
    Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004; 50: 233846.
  • 49
    Herrak P, Gortz B, Hayer S, Redlich K, Reiter E, Gasser J, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor–mediated arthritis. Arthritis Rheum 2004; 50: 232737.